{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loperamide+Hydrochloride", "query": { "intervention": "Loperamide Hydrochloride" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Loperamide+Hydrochloride&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T07:04:52.193Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00806299", "title": "Loperamide Grapefruit Juice Interaction PK Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction" ], "interventions": [ { "name": "Loperamide / Red Grapefruit Juice", "type": "DRUG" }, { "name": "Loperamide/ White Grapefruit Juice", "type": "DRUG" }, { "name": "Loperamide / Pink Grapefruit Juice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Consumer and Personal Products Worldwide", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 33, "start_date": "2008-11", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2011-10-06", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806299" }, { "nct_id": "NCT05528848", "title": "Multi-System Analysis of Opioid Receptor Binding", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Opioid Use Disorder" ], "interventions": [ { "name": "Carfentanil, C-11", "type": "DRUG" }, { "name": "Naloxone", "type": "DRUG" }, { "name": "Loperamide Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2022-09-20", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05528848" }, { "nct_id": "NCT03030417", "title": "Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "LMP744", "type": "DRUG" }, { "name": "Ondansetron", "type": "OTHER" }, { "name": "Olanzapine", "type": "OTHER" }, { "name": "Lorazepam", "type": "OTHER" }, { "name": "Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate", "type": "OTHER" }, { "name": "Loperamide", "type": "OTHER" }, { "name": "Diphenhydramine", "type": "OTHER" }, { "name": "Steroid", "type": "OTHER" }, { "name": "Epinephrine", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-02-27", "completion_date": "2023-10-12", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Pittsburgh, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030417" }, { "nct_id": "NCT07756359", "title": "Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pouch, Ileal", "Pouches, Ileoanal", "Bowel Diseases, Inflammatory" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Diphenoxylate/Atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2026-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 5, "location_summary": "Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07756359" }, { "nct_id": "NCT00387894", "title": "Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Brain Tumors" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Prados", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2007-01", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387894" }, { "nct_id": "NCT04172597", "title": "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Solid Tumor", "Glioblastome Multiforme" ], "interventions": [ { "name": "Poziotinib Hydrochloride", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-12-23", "completion_date": "2022-03-29", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04172597" }, { "nct_id": "NCT00003057", "title": "Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer", "Diarrhea" ], "interventions": [ { "name": "loperamide hydrochloride", "type": "DRUG" }, { "name": "octreotide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 500, "start_date": "1997-03-26", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 33, "location_summary": "La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003057" }, { "nct_id": "NCT00778115", "title": "Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Loperamide HCl 2 mg and simethicone 125 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2004-11", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2008-10-23", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778115" }, { "nct_id": "NCT01391962", "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Alveolar Soft Part" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "OTHER" }, { "name": "Promethazine", "type": "OTHER" }, { "name": "Benzodiazepine", "type": "OTHER" }, { "name": "Filgrastim", "type": "OTHER" }, { "name": "Sargramostim", "type": "OTHER" }, { "name": "Lomotil", "type": "OTHER" }, { "name": "Loperamide", "type": "OTHER" }, { "name": "Vitamin B6", "type": "OTHER" }, { "name": "Aquaphor", "type": "OTHER" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Levothyroxine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "16 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2011-07-18", "completion_date": "2026-01-16", "has_results": true, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391962" }, { "nct_id": "NCT03094052", "title": "Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Breast Adenocarcinoma", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Crofelemer", "type": "DRUG" }, { "name": "Diphenoxylate/Atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-10-09", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-09-11T07:04:52.193Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094052" } ] }